Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 15/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.59 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.59 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16736215 | 1.00 | PIK3C3 (0.59) | PIK3C3PIK3CAPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL30531391 | 1.00 | PIK3C3 (0.59) | PIK3C3PIK3CAPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL16735892 | 0.89 | PIK3C3 (0.60) | PIK3C3PIK3CAPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL30531356 | 0.89 | PIK3C3 (0.60) | PIK3C3PIK3CAPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL16735997 | 0.89 | PIK3C3 (0.60) | PIK3C3PIK3CAPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL16735999 | 0.89 | PIK3C3 (0.60) | PIK3C3PIK3CAPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL16735895 | 0.89 | PIK3C3 (0.60) | PIK3C3PIK3CAPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL16736265 | 0.88 | PIK3C3 (0.57) | PIK3C3PIK3CAPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL16736262 | 0.88 | PIK3C3 (0.57) | PIK3C3PIK3CAPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL30531422 | 0.88 | PIK3C3 (0.57) | PIK3C3PIK3CAPIK3CBPIK3CGPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150148328-A1 | Novel 2,3-Dihydro-1H-imidazopyrimidin-5-one and this 1,2,3,4-tetrahydropyrimidopyrimidin-6-one Derivatives Comprising a Substituted Morpholine, Preparation Thereof and Pharmaceutical Use Thereof | SANOFI (FR) | 2015-05-28 | — | — | US | claimed |
| US-11739100-B2 | 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof | SANOFI (FR) | 2023-08-29 | — | — | US | disclosed |
| US-11739100-B2 | 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof | SANOFI (FR) | 2023-08-29 | — | — | US | disclosed |
| US-11739100-B2 | 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof | SANOFI (FR) | 2023-08-29 | — | — | US | disclosed |
| US-20190292205-A1 | Novel 2,3-Dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one Derivatives Comprising a Substituted Morpholine, Preparation Thereof and Pharmaceutical Use Thereof | SANOFI (FR) | 2019-09-26 | — | — | US | disclosed |
| US-10253043-B2 | 2,3-dihydro-1H-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof | SANOFI (FR) | 2019-04-09 | — | — | US | disclosed |
| US-10253043-B2 | 2,3-dihydro-1H-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof | SANOFI (FR) | 2019-04-09 | — | — | US | disclosed |
| US-20150148328-A1 | Novel 2,3-Dihydro-1H-imidazopyrimidin-5-one and this 1,2,3,4-tetrahydropyrimidopyrimidin-6-one Derivatives Comprising a Substituted Morpholine, Preparation Thereof and Pharmaceutical Use Thereof | SANOFI (FR) | 2015-05-28 | — | — | US | disclosed |
| US-20150148328-A1 | Novel 2,3-Dihydro-1H-imidazopyrimidin-5-one and this 1,2,3,4-tetrahydropyrimidopyrimidin-6-one Derivatives Comprising a Substituted Morpholine, Preparation Thereof and Pharmaceutical Use Thereof | SANOFI (FR) | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148328-A1 | Novel 2,3-Dihydro-1H-imidazopyrimidin-5-one and this 1,2,3,4-tetrahydropyrimidopyrimidin-6-one Derivatives Comprising a Substituted Morpholine, Preparation Thereof and Pharmaceutical Use Thereof | RDX, MTX1, CCNY | PIK3C3 3029/4885PIK3CA 4259/4885PIK3CB 4745/4885 |
| US-10253043-B2 | 2,3-dihydro-1H-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof | MTX1, RDX, MTX2 | PIK3C3 2704/4885PIK3CA 3685/4885PIK3CB 4600/4885 |
| US-11739100-B2 | 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof | CBR3, MTX1, CBR1 | PIK3C3 2701/4885PIK3CA 3644/4885PIK3CB 4637/4885 |
| US-20190292205-A1 | Novel 2,3-Dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one Derivatives Comprising a Substituted Morpholine, Preparation Thereof and Pharmaceutical Use Thereof | CCNY, CBR3, CBR1 | PIK3C3 2808/4885PIK3CA 3887/4885PIK3CB 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.